drugset
drugset / Trial / NCT05503511

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

NCT05503511 ↗

Phase 1 Completed 50 enrolled NeuroPro Therapeutics, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.

Timeline

Start
2022-10-20
Primary completion
2023-03-17
Completion
2023-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NPT 2042 Unknown 10 mg Oral
Subject NPT 2042 Unknown 20 mg Oral
Subject NPT 2042 Unknown 40 mg Oral
Subject NPT 2042 Unknown 50 mg Oral
Subject NPT 2042 Unknown 80 mg Oral
Subject NPT 2042 Unknown 160 mg Oral

Indications

Alzheimer disease epilepsy